Seroprevalence Surgery of Anti-SARS-CoV-2 Antibodies Based on COVID-19 Vaccine Type in Academy Community, East Kalimantan, Indonesia

Abstract

BACKGROUND OF THE STUDY: The implementation of the vaccine on a large scale has almost reached all provinces in Indonesia. East Kalimantan, one of the provinces affected by COVID-19, has also implemented a vaccine program. Seroprevalence surveys are essential to describe the success of vaccine program based on antibody titre test.
 AIM OF THE STUDY: This study aims to determine the anti-SARS-CoV-2 antibody titre value based on the type of vaccine received by the academic community in Samarinda, one of the cities most affected by COVID-19 in East Kalimantan.
 METHODOLOGY: The study was population-based. The study sampled 100 people from the community. Participants must be in good health, aged 16-60, with a positive COVID-19 test, no comorbid illnesses or other chronic problems, no blood transfusions, and most importantly, have received the least initial dosage of immunization. The data will be analyzed using SPSS 26 and STATA 16. A normality test and Tobit regression test to determine the antibody distribution in each vaccine type. 
 RESULTS: The results showed that Moderna COVID-19 Vaccine provided a significant (p=0.001) increase in antibody prediction of 1090 U/ml (95% CI: 764-1416), while Pfizer provided a significant (p=0.000) rise of 766 U/ml (95% CI: 307-1226).
 CONCLUSION: According to the results of a seroprevalence survey conducted among the academic community in East Kalimantan, receivers of inactivated vaccinations outnumbered those of mRNA and vector-based vaccines. It can be determined that booster immunizations for students and academic staff are required to guard against COVID-19 infection. As boosters, both Moderna's COVID-19 Vaccine and Pfizer's COVID-19 Vaccine are strongly recommended.